Clinical trial NCT05714592: Evaluation of Optical Genome Mapping in Phi Negative Myeloproliferative Neoplasia in the Detection of Acquired Cytogenetic Abnormalities
Official title: Evaluation of Optical Genome Mapping in Phi Negative Myeloproliferative Neoplasia in the Detection of Acquired Cytogenetic Abnormalities
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Myeloproliferative Neoplasm
Optical Genome Mapping
Cytogenetics
Clonality
Prognostic Stratification
Keywords: Myeloproliferative Neoplasm
Optical genome mapping
Cytogenetics
Clonality
Prognostic stratification
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
Collaborators: name: Hôpital Jeanne de Flandre LIlle
name: Centre Henri Becquerel
First posted: 2023-02-06
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Standard cytogenetics (CBA +/- FISH) is of diagnostic and prognostic interest in Ph- MPN. However, its value is limited by the low frequency of detected abnormalities. The development of tools to increase the sensitivity of detection of chromosomal alterations is therefore particularly adapted to these pathologies. Optical genome mapping (OGM) is a high resolution "long read" technique that allows the identification of structural and copy number variations at the whole genome level. Several recent studies suggest that OGM is a future tool for cytogenetic characterization of haematological disorders. Its ability to describe structural abnormalities, including balanced ones, represents a major advantage over currently used technologies. Thus, OGM seems to be the key tool for cytogenetics of haematological malignancies in the coming years, making it possible to replace, under certain conditions, not only karyotype and FISH, but CMA and even RT-MLPA for the search for fusion transcripts, thus filling in the gaps in these techniques while maintaining their advantages.

To define the place of this technology in Ph- MPN, the investigators will perform a OGM analysis on patients with Ph-MPN for whom bone marrow exploration is scheduled. These results will be compared with those of standard cytogenetics (CBA +/- FISH).


Eligibility criteria: Inclusion Criteria:

* Patient 18 years of age or older
* Diagnosis or follow-up of polycythemia vera, essential thrombocythemia or primary or secondary myelofibrosis
* Requires bone marrow cytogenetics at diagnosis or follow-up
* Understanding of the French language
* Information of the patient and collection of no objection
* Person affiliated to a social security regime

Exclusion Criteria:

* Patient with BCR::ABL positive myeloproliferative neoplasia.
* Person with a medical history that may impair the ability to understand the information notice

Primary outcomes:
measure: Number of patients with the same abnormalises detected with both OGM and standard cytogenetics
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: Centre Hospitalier Universitaire d'Amiens
state: Picardie
Study officials:
References: